Lifecore Biomedical, Inc. (LFCR)
| Market Cap | 191.88M |
| Revenue (ttm) | 129.46M |
| Net Income (ttm) | -34.50M |
| Shares Out | 37.48M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 158,083 |
| Open | 5.08 |
| Previous Close | 5.08 |
| Day's Range | 5.03 - 5.17 |
| 52-Week Range | 3.63 - 8.98 |
| Beta | 0.88 |
| Analysts | Buy |
| Price Target | 5.50 (+7.42%) |
| Earnings Date | Aug 7, 2026 |
About LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk... [Read more]
Financial Performance
In 2025, Lifecore Biomedical's revenue was $129.46 million, an increase of 0.46% compared to the previous year's $128.87 million. Losses were -$34.50 million, -22.22% less than in 2025.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for LFCR stock is "Buy." The 12-month stock price target is $5.5, which is an increase of 7.42% from the latest price.
News
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHASKA, Minn., April 22, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), tod...
Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit
CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System ...
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial R...
Lifecore Biomedical Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
The company has transformed into a pure-play life sciences CDMO, focusing on sterile injectables and hyaluronic acid fermentation. With reinforced mid-term revenue and margin targets, a robust late-stage pipeline, and new tech transfer agreements, growth is driven by reshoring trends and expanding partnerships. Capacity utilization and operational efficiency are set to improve through 2029.
Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lifecore Biomedical, Inc. The investigation focuses on Lifecore Biomedica...
Lifecore Biomedical Transcript: Transition period
Revenue and EBITDA margins grew strongly in 2025, driven by pipeline expansion, operational efficiencies, and new business wins. 2026 guidance anticipates stable revenue and margin progression, with significant growth expected from 2027 as major customer demand and late-stage pipeline launches accelerate.
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
-- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer P...
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen ™ , its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug B...
Lifecore Biomedical to Participate at DCAT Week 2026
CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), tod...
HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced ...
Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary d...
Lifecore Biomedical to be Added to Nasdaq Biotech Index
CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer
Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference
CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...
Lifecore Biomedical Transcript: Stephens Annual Investment Conference
Transitioning to a standalone CDMO, the company has invested in capacity, revamped leadership, and implemented new commercial strategies. With only 20% of $300M capacity utilized, a strong late-stage pipeline, and a focus on margin expansion, it targets 12% CAGR and 25%+ EBITDA margins midterm.
Lifecore Biomedical Transcript: Jefferies London Healthcare Conference 2025
Lifecore Biomedical outlined an aggressive growth strategy, leveraging recent capital investments and a revamped commercial approach to target a 12% revenue CAGR and >25% EBITDA margins over the next 3–4 years. The company is well-positioned in a growing CDMO market, with a robust late-stage pipeline and improved liquidity.
Lifecore Biomedical to Participate in Upcoming Investor Conferences
CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced ...
Lifecore Biomedical Earnings Call Transcript: Q1 2026
Q3 2025 saw 26% revenue growth, improved margins, and new business wins, with a strong late-stage pipeline and cost reductions driving a positive outlook. Guidance for the transition period was reaffirmed, with further margin expansion and revenue growth expected.
Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update
-- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025 , Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customer...
Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025
CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company
Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product